OmniAb, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OABI Nasdaq 2836 www.omniab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OmniAb, Inc.

OmniAb to Host Investor & Analyst Day on October 6, 2026 - Sep 14th, 2026 6:00 am
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? - Aug 28th, 2026 2:02 pm
VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology - Aug 28th, 2026 1:00 pm
OmniAb to Participate in Upcoming Investor Conferences - Aug 26th, 2026 6:00 am
Why Eli Lilly (LLY) Stock Is Up Today - Aug 18th, 2026 4:37 pm
Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals - Aug 18th, 2026 4:11 pm
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - Aug 17th, 2026 2:47 pm
Top Midday Gainers - Aug 17th, 2026 11:40 am
OmniAb lifts 2026 cash outlook following licensing momentum - Aug 17th, 2026 5:01 am
OmniAb Raises 2026 Financial Guidance - Aug 17th, 2026 4:06 am
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company - Aug 17th, 2026 4:01 am
OmniAb (OABI) Q2 2026 Earnings Call Transcript - Aug 14th, 2026 4:58 am
OmniAb Q2 Earnings Call Highlights - Aug 7th, 2026 12:04 am
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... - Aug 6th, 2026 11:06 pm
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates - Aug 6th, 2026 5:10 pm
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights - Aug 6th, 2026 2:05 pm
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies - Aug 6th, 2026 12:30 pm
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - Jul 27th, 2026 1:37 pm
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - Jul 27th, 2026 5:00 am